Clinical Trials Directory

Trials / Unknown

UnknownNCT01045408

The Effect of Berry Extract on Helicobacter Pylori Eradication

The Adjuvant Effect of Berry Extract on Triple Therapy for Helicobacter Pylori Eradication

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Shin Kong Wu Ho-Su Memorial Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Helicobacter pylori (HP) is the major risk factors of gastritis, gastric ulcers, duodenal ulcers, mucosa associated lymphoid tissue lymphoma and gastric cancer. Helicobacter pylori are found in 70-90% of the population in developing countries and in 25-50% of developed countries.

Detailed description

One-week of triple therapy composed of a proton pump inhibitor plus two antibiotics is currently regarded as the gold standard for HP eradication. However, the eradication rate continues to be disappointing. Poor patient compliance and bacterial resistance are the main factors contributing to treatment failure. Therefore, it is urgently necessary to develop a non-antibiotic alternative therapy to increase the eradication rates of Helicobacter pylori. Some literatures reported that cranberry may inhibit Helicobacter pylori adhesion to the human gastric mucus and may reduce Helicobacter pylori infection in adults. The aims of his experiment were to explore the impact of berry extract on triple therapy for Helicobacter pylori eradication.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTBerry extractBerry extract for weeks

Timeline

Start date
2009-01-01
Primary completion
2009-12-01
Completion
2010-06-01
First posted
2010-01-11
Last updated
2010-01-14

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01045408. Inclusion in this directory is not an endorsement.